98%
921
2 minutes
20
Background And Objective: Severe asthma is a heterogeneous disease with subtype classification according to dominant airway infiltrates, including eosinophilic (Type 2 high), or non-eosinophilic asthma. Non-eosinophilic asthma is further divided into paucigranulocytic or neutrophilic asthma characterized by elevated neutrophils, and mixed Type 1 and Type 17 cytokines in the airways. Severe non-eosinophilic asthma has few effective treatments and many patients do not qualify for biologic therapies. The cystic fibrosis transmembrane conductance regulator (CFTR) is dysregulated in multiple respiratory diseases including cystic fibrosis and chronic obstructive pulmonary disease and has proven a valuable therapeutic target. We hypothesized that the CFTR may also play a role in non-eosinophilic asthma.
Methods: Patient-derived human bronchial epithelial cells (hBECs) were isolated and differentiated at the air-liquid interface. Single cell RNA-sequencing (scRNAseq) was used to identify epithelial cell subtypes and transcriptional activity. Ion transport was investigated with Ussing chambers and immunofluorescent quantification of ionocyte abundance in human airway epithelial cells and murine models of asthma.
Results: We identified that hBECs from patients with non-eosinophilic asthma had reduced CFTR function, and did not differentiate into CFTR-expressing ionocytes compared to those from eosinophilic asthma or healthy donors. Similarly, ionocytes were also diminished in the airways of a murine model of neutrophilic-dominant but not eosinophilic asthma. Treatment of hBECs from healthy donors with a neutrophilic asthma-like inflammatory cytokine mixture led to a reduction in ionocytes.
Conclusion: Inflammation-induced loss of CFTR-expressing ionocytes in airway cells from non-eosinophilic asthma may represent a key feature of disease pathogenesis and a novel drug target.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11688627 | PMC |
http://dx.doi.org/10.1111/resp.14833 | DOI Listing |
Clin Exp Immunol
September 2025
Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disorder of the sinonasal mucosa, predominantly characterized by epithelial dysfunction and chronic heterogeneous mucosal inflammation. CRSwNP and asthma are common comorbidities with overlapping pathophysiology, epithelial impairment and activation of downstream type 2 inflammation. Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that sits at the top of the immunological cascade and initiates and amplifies type 2-dependent and -independent inflammatory responses.
View Article and Find Full Text PDFJ Asthma
September 2025
Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Objective: Small airway dysfunction (SAD) is a common feature of bronchial asthma. However, its association with asthma phenotypes remains poorly understood. This study aimed to assess the prevalence of oscillometry-defined SAD in steroid-naïve adult bronchial asthma and to explore its association with asthma phenotypes based on peripheral blood eosinophil count (BEC).
View Article and Find Full Text PDFFront Allergy
June 2025
Unit of Respiratory Immunopharmacology, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Background: Azithromycin (AZM) effectively reduces asthma exacerbations and enhances bronchial epithelial cell (BEC) antiviral immunity . However, its clinical impact on different asthma phenotypes is not fully elucidated and differences in treatment response to AZM may be attributable to differences in immune activation to rhinovirus (RV) infection in different inflammatory asthma phenotypes.
Objectives: To explore bronchial epithelial antiviral properties in response to AZM treatment in eosinophilic and non-eosinophilic as well as atopic and non-atopic asthma phenotypes, and to investigate the effects of AZM on the release of RV-induced alarmins and pro-inflammatory cytokines in these asthma phenotypes.
Allergy Asthma Clin Immunol
June 2025
Department of Allergy and Clinical Immunology, Ajou University School of Medicine, 206 Worldcup-Ro, Yeongtong-Gu, Suwon, 16499, Korea.
Immunoglobulin E (IgE) is a key molecule that induces mast cell activation in allergic inflammation and contributes to type 2/eosinophilic inflammation in asthmatic airways. This cross-sectional study investigated the role of local IgE in asthmatic airways according to atopy, asthma control, and eosinophilic inflammation. A total of 31 adult patients with moderate-to-severe asthma were enrolled.
View Article and Find Full Text PDFLife (Basel)
June 2025
Department of Internal Medicine, Regional Institute of Gastroenterology (IRGH), 400394 Cluj-Napoca, Romania.
Asthma exacerbations are acute worsening episodes in individuals with bronchial asthma, frequently necessitating emergency hospital care. Early differentiation between eosinophilic (≥150 eosinophils/mm) and non-eosinophilic (<150 eosinophils/mm) subtypes plays a crucial role in treatment decisions and identifying patients eligible for biologic therapies. The ExBA Study explored variations in complete blood count (CBC) parameters and derived cellular ratios-namely the neutrophil-to-lymphocyte (NLR), thrombocyte-to-lymphocyte (TLR), and eosinophil-to-leukocyte ratios (ELR)-in adults hospitalized with severe asthma exacerbations.
View Article and Find Full Text PDF